| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Silvestrol is a naturally occuring flavagline analog isolated from the genus of Aglaia, it acts as a eukaryotic translation initiation factor 4A (eIF4A) inhibitor and exhibits anti-cancer activity in vitro and in vivo. Silvestrol induces early autophagy and apoptosis in human melanoma cells. Silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
| ln Vitro |
Translation inhibitors that specifically target eIF4A include silvestrol. With IC50 values ranging from 1 to 7 nM, silvestrol demonstrates strong cytotoxic action against numerous human cancer cell lines, including those from the prostate, breast, and lung [1]. LNCaP cell colonies were substantially fewer in number when sivestrol was used. Via the mitochondrial route, silvestrol (30 nM, 120 nM) causes apoptosis in LNCaP cells. Silvestrol-induced apoptosis involves Apaf-1, Caspase-2, Caspase-9, and Caspase-10, but not Apaf-3 or Caspase-7 [2]. Apoptosis and caspase-3 activation are induced by silvestrol in a dose- and time-dependent manner. In ATG7-null mouse embryonic fibroblasts (MEFs) deficient in functioning autophagy proteins, silvestrol-mediated cell death is reduced [3]. When compared to control cells, silvestrol (50 nM) causes nearly-static cell indices and an instantaneous inhibitory action. Higher doses of silvestrol (50 nM) decreased cell proliferation, whereas silvestrol (6.25 nM) increased proliferation more than vehicle control-treated cells. When combined with CDDP, silvestrol and episilvestrol exhibit synergistic effects [4].
|
|---|---|
| ln Vivo |
B cells xenografted from mice do not produce less human IgG in response to silvestrol (1.5 mg/kg, ip). Comparing silvestrol to a vehicle, survival was considerably extended. None of the mice treated with silvestrol had such lymphocytic infiltrates in their spleens, and upon necropsy, the mice displayed no other obvious symptoms of lymphoma [5].
|
| References |
|
| Additional Infomation |
Silvestrol is an organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity. It has a role as a metabolite and an antineoplastic agent. It is an organic heterotricyclic compound, a member of dioxanes, an ether and a methyl ester.
Silvestrol has been reported in Aglaia foveolata and Aglaia silvestris with data available. |
| Molecular Formula |
C34H38O13
|
|---|---|
| Molecular Weight |
654.6577
|
| Exact Mass |
654.231
|
| CAS # |
697235-38-4
|
| Related CAS # |
Silvestrol aglycone;960365-65-5;Episilvestrol;697235-39-5
|
| PubChem CID |
11787114
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
800.8±65.0 °C at 760 mmHg
|
| Flash Point |
252.4±27.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.652
|
| LogP |
2.32
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
47
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CO[C@H]1[C@@H](O[C@H](CO1)[C@@H](CO)O)OC2=CC3=C(C(=C2)OC)[C@@]4([C@@H]([C@@H]([C@H]([C@@]4(O3)C5=CC=C(C=C5)OC)C6=CC=CC=C6)C(=O)OC)O)O
|
| InChi Key |
GVKXFVCXBFGBCD-QKDMMWSPSA-N
|
| InChi Code |
InChI=1S/C34H38O13/c1-40-20-12-10-19(11-13-20)34-27(18-8-6-5-7-9-18)26(30(38)42-3)29(37)33(34,39)28-23(41-2)14-21(15-24(28)47-34)45-32-31(43-4)44-17-25(46-32)22(36)16-35/h5-15,22,25-27,29,31-32,35-37,39H,16-17H2,1-4H3/t22-,25-,26-,27-,29-,31-,32-,33+,34+/m1/s1
|
| Chemical Name |
methyl (1R,2R,3S,3aR,8bS)-6-[[(2S,3R,6R)-6-[(1R)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 6.6 mg/mL (~10.08 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5275 mL | 7.6376 mL | 15.2751 mL | |
| 5 mM | 0.3055 mL | 1.5275 mL | 3.0550 mL | |
| 10 mM | 0.1528 mL | 0.7638 mL | 1.5275 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA